| mu-opioid receptor MOR |
FLUPHENAZINE |
Opiate mu |
67% |
20.745uM |
8.421uM |
View
|
| phosphodiesterase 3B |
MC 288769 |
Phosphodiesterase PDE3 |
67% |
23.569uM |
NoneNone |
View
|
| phosphodiesterase 3A |
MC 288769 |
Phosphodiesterase PDE3 |
67% |
23.569uM |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2A |
R-(+)-PROPRANOLOL |
Serotonin 5-HT2A |
67% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 1a |
GENTIAN VIOLET |
Adrenergic alpha1A |
67% |
NoneNone |
NoneNone |
View
|
| epidermal growth factor receptor |
ISOTRETINOIN |
Protein Tyrosine Kinase, EGF Receptor |
67% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, beta 2 |
LYSERGOL |
Adrenergic beta2 |
67% |
NoneNone |
NoneNone |
View
|
| dopamine receptor 2 |
MEPAZINE |
Dopamine D2L |
67% |
NoneNone |
NoneNone |
View
|
| thromboxane A synthase 1 |
VINCRISTINE |
Thromboxane Synthetase |
67% |
NoneNone |
NoneNone |
View
|
| thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) |
VINCRISTINE |
Thromboxane Synthetase |
67% |
NoneNone |
NoneNone |
View
|
| opioid receptor, kappa 1 |
QUINACRINE |
Opiate kappa |
67% |
NoneNone |
NoneNone |
View
|
| 5-hydroxytryptamine receptor 6 |
SERTRALINE |
Serotonin 5-HT6 |
67% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
OXICONAZOLE |
Calcium Channel Type L, Benzothiazepine |
67% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
OXICONAZOLE |
Calcium Channel Type L, Benzothiazepine |
67% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
OXICONAZOLE |
Calcium Channel Type L, Benzothiazepine |
67% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
OXICONAZOLE |
Calcium Channel Type L, Benzothiazepine |
67% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
OXICONAZOLE |
Calcium Channel Type L, Benzothiazepine |
67% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
OXICONAZOLE |
Calcium Channel Type L, Benzothiazepine |
67% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
OXICONAZOLE |
Calcium Channel Type L, Benzothiazepine |
67% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
OXICONAZOLE |
Calcium Channel Type L, Benzothiazepine |
67% |
NoneNone |
NoneNone |
View
|
| 3-hydroxy-3-methylglutaryl-Coenzyme A reductase |
TRANS-PLATINUM(II)DIAMMINE DICHLORIDE |
HMG-CoA Reductase |
67% |
NoneNone |
NoneNone |
View
|
| 3-hydroxy-3-methylglutaryl-Coenzyme A reductase |
TRANS-PLATINUM(II)DIAMMINE DICHLORIDE |
HMG-CoA Reductase |
67% |
NoneNone |
NoneNone |
View
|
| 5-hydroxytryptamine receptor 6 |
HEXACHLOROPHENE |
Serotonin 5-HT6 |
67% |
NoneNone |
NoneNone |
View
|
| phosphodiesterase 5A, cGMP-specific |
ZINC CHLORIDE |
Phosphodiesterase PDE5 |
67% |
NoneNone |
NoneNone |
View
|
| phosphodiesterase 5A, cGMP-specific |
ZINC CHLORIDE |
Phosphodiesterase PDE5 |
67% |
NoneNone |
NoneNone |
View
|
| cytochrome P450, family 3, subfamily a, polypeptide 13 |
DESLORATADINE |
CYP450-3A4 Inhibition |
67% |
NoneNone |
NoneNone |
View
|
| Cytochrom P450-2D6 monooxygenase |
HYDROXYCHLOROQUINE |
CYP450-2D6 Inhibition |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IV, beta |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel associated protein 1 |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel associated protein 2 |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type III, beta |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type I, alpha |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IX, alpha |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type VII, alpha |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
HALOPERIDOL |
Calcium Channel Type L, Benzothiazepine |
71% |
1.717uM |
1.527uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
HALOPERIDOL |
Calcium Channel Type L, Benzothiazepine |
71% |
1.717uM |
1.527uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
HALOPERIDOL |
Calcium Channel Type L, Benzothiazepine |
71% |
1.717uM |
1.527uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
HALOPERIDOL |
Calcium Channel Type L, Benzothiazepine |
71% |
1.717uM |
1.527uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
HALOPERIDOL |
Calcium Channel Type L, Benzothiazepine |
71% |
1.717uM |
1.527uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
HALOPERIDOL |
Calcium Channel Type L, Benzothiazepine |
71% |
1.717uM |
1.527uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
HALOPERIDOL |
Calcium Channel Type L, Benzothiazepine |
71% |
1.717uM |
1.527uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
HALOPERIDOL |
Calcium Channel Type L, Benzothiazepine |
71% |
1.717uM |
1.527uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
HALOPERIDOL |
Calcium Channel Type L, Benzothiazepine |
71% |
1.717uM |
1.527uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
HALOPERIDOL |
Calcium Channel Type L, Benzothiazepine |
71% |
1.717uM |
1.527uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
HALOPERIDOL |
Calcium Channel Type L, Benzothiazepine |
71% |
1.717uM |
1.527uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
HALOPERIDOL |
Calcium Channel Type L, Benzothiazepine |
71% |
1.717uM |
1.527uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
HALOPERIDOL |
Calcium Channel Type L, Benzothiazepine |
71% |
1.717uM |
1.527uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
HALOPERIDOL |
Calcium Channel Type L, Benzothiazepine |
71% |
1.717uM |
1.527uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
HALOPERIDOL |
Calcium Channel Type L, Benzothiazepine |
71% |
1.717uM |
1.527uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
HALOPERIDOL |
Calcium Channel Type L, Benzothiazepine |
71% |
1.717uM |
1.527uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
HALOPERIDOL |
Calcium Channel Type L, Benzothiazepine |
71% |
1.717uM |
1.527uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
HALOPERIDOL |
Calcium Channel Type L, Benzothiazepine |
71% |
1.717uM |
1.527uM |
View
|
| adrenergic receptor, alpha 2b |
DESLORATADINE |
Adrenergic alpha2B |
71% |
2.146uM |
.98uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
HALOPERIDOL |
Calcium Channel Type L, Benzothiazepine |
71% |
1.717uM |
1.527uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
HALOPERIDOL |
Calcium Channel Type L, Benzothiazepine |
71% |
1.717uM |
1.527uM |
View
|
| arachidonate 15-lipoxygenase, second type |
MONOBENZONE |
Lipoxygenase 15-LO |
71% |
4.892uM |
NoneNone |
View
|
| arachidonate 15-lipoxygenase |
MONOBENZONE |
Lipoxygenase 15-LO |
71% |
4.892uM |
NoneNone |
View
|
| arachidonate 15-lipoxygenase |
MONOBENZONE |
Lipoxygenase 15-LO |
71% |
4.892uM |
NoneNone |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
GENTIAN VIOLET |
Calcium Channel Type L, Phenylalkylamine |
71% |
3.441uM |
3.346uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
GENTIAN VIOLET |
Calcium Channel Type L, Phenylalkylamine |
71% |
3.441uM |
3.346uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
GENTIAN VIOLET |
Calcium Channel Type L, Phenylalkylamine |
71% |
3.441uM |
3.346uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
GENTIAN VIOLET |
Calcium Channel Type L, Phenylalkylamine |
71% |
3.441uM |
3.346uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
GENTIAN VIOLET |
Calcium Channel Type L, Phenylalkylamine |
71% |
3.441uM |
3.346uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
GENTIAN VIOLET |
Calcium Channel Type L, Phenylalkylamine |
71% |
3.441uM |
3.346uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
GENTIAN VIOLET |
Calcium Channel Type L, Phenylalkylamine |
71% |
3.441uM |
3.346uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
GENTIAN VIOLET |
Calcium Channel Type L, Phenylalkylamine |
71% |
3.441uM |
3.346uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
GENTIAN VIOLET |
Calcium Channel Type L, Phenylalkylamine |
71% |
3.441uM |
3.346uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
GENTIAN VIOLET |
Calcium Channel Type L, Phenylalkylamine |
71% |
3.441uM |
3.346uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
GENTIAN VIOLET |
Calcium Channel Type L, Phenylalkylamine |
71% |
3.441uM |
3.346uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
GENTIAN VIOLET |
Calcium Channel Type L, Phenylalkylamine |
71% |
3.441uM |
3.346uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
GENTIAN VIOLET |
Calcium Channel Type L, Phenylalkylamine |
71% |
3.441uM |
3.346uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
GENTIAN VIOLET |
Calcium Channel Type L, Phenylalkylamine |
71% |
3.441uM |
3.346uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
GENTIAN VIOLET |
Calcium Channel Type L, Phenylalkylamine |
71% |
3.441uM |
3.346uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
GENTIAN VIOLET |
Calcium Channel Type L, Phenylalkylamine |
71% |
3.441uM |
3.346uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
GENTIAN VIOLET |
Calcium Channel Type L, Phenylalkylamine |
71% |
3.441uM |
3.346uM |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
GENTIAN VIOLET |
Calcium Channel Type L, Phenylalkylamine |
71% |
3.441uM |
3.346uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
GENTIAN VIOLET |
Calcium Channel Type L, Phenylalkylamine |
71% |
3.441uM |
3.346uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
GENTIAN VIOLET |
Calcium Channel Type L, Phenylalkylamine |
71% |
3.441uM |
3.346uM |
View
|
| solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
MOSAPRIDE |
Serotonin Transporter |
71% |
3.8117uM |
2.0249uM |
View
|
| amiloride-sensitive cation channel 5, intestinal |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type III, beta |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type VIII, alpha polypeptide |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type XI, alpha |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type I, beta |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type 10, alpha polypeptide |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IV, alpha polypeptide |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type V, alpha polypeptide |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type II, beta |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 gamma |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 beta |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type XI, alpha |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1, gamma |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1, delta |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type X, alpha |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IX, alpha |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage gated, type VIII, alpha |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type VII, alpha |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IV, beta |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IV, alpha |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type III, alpha |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type II, beta |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type II, alpha 2 |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type I, beta |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type I, alpha |
LABETALOL |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| adenosine A2a receptor |
GENISTEIN |
Adenosine A2A |
69% |
17.442uM |
9.792uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2B |
EPERISONE |
Serotonin 5-HT2B |
69% |
NoneNone |
NoneNone |
View
|
| dopamine receptor 2 |
VERAPAMIL |
Dopamine D2L |
69% |
NoneNone |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2B |
1-(2-METHOXYBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE |
Serotonin 5-HT2B |
69% |
NoneNone |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2A |
RWJ-68354 |
Serotonin 5-HT2A |
69% |
NoneNone |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2B |
RWJ-68354 |
Serotonin 5-HT2B |
69% |
NoneNone |
NoneNone |
View
|
| monoamine oxidase A |
LEFLUNOMIDE |
Monoamine Oxidase MAOA |
69% |
20.696uM |
NoneNone |
View
|
| monoamine oxidase A |
LEFLUNOMIDE |
Monoamine Oxidase MAOA |
69% |
20.696uM |
NoneNone |
View
|
| cholinergic receptor, muscarinic 3 |
TROPISETRON |
Muscarinic M3 |
69% |
NoneNone |
NoneNone |
View
|
| Sigma-2 Receptor |
QUINACRINE |
Sigma2 |
69% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 1d (Non-specific probe) |
SERTRALINE |
Adrenergic alpha1D |
69% |
NoneNone |
NoneNone |
View
|
| dopamine receptor D3 |
ORPHENADRINE |
Dopamine D3 |
69% |
NoneNone |
NoneNone |
View
|
| aldo-keto reductase family 1, member B4 (aldose reductase) |
NIFURSOL |
Aldose Reductase |
69% |
NoneNone |
NoneNone |
View
|
| aldo-keto reductase family 1, member B1 (aldose reductase) |
NIFURSOL |
Aldose Reductase |
69% |
NoneNone |
NoneNone |
View
|
| aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase) |
NIFURSOL |
Aldose Reductase |
69% |
NoneNone |
NoneNone |
View
|
| aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) |
NIFURSOL |
Aldose Reductase |
69% |
NoneNone |
NoneNone |
View
|
| aldo-keto reductase family 1, member B4 (aldose reductase) |
CHLORAMBUCIL |
Aldose Reductase |
69% |
9.413uM |
NoneNone |
View
|
| aldo-keto reductase family 1, member B1 (aldose reductase) |
CHLORAMBUCIL |
Aldose Reductase |
69% |
9.413uM |
NoneNone |
View
|
| aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase) |
CHLORAMBUCIL |
Aldose Reductase |
69% |
9.413uM |
NoneNone |
View
|
| aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) |
CHLORAMBUCIL |
Aldose Reductase |
69% |
9.413uM |
NoneNone |
View
|
| adenosine A2a receptor |
SB-203580 |
Adenosine A2A |
69% |
6.068uM |
3.407uM |
View
|
| matrix metalloproteinase 1 (interstitial collagenase) |
NISOLDIPINE |
Protease, Matrix Metalloprotease-1 (MMP-1) |
69% |
NoneNone |
NoneNone |
View
|
| opioid receptor, delta 1 |
ASTEMIZOLE |
Opiate delta |
69% |
12.979uM |
4.575uM |
View
|
| cholinergic receptor, muscarinic 4 |
DOXAZOSIN |
Muscarinic M4 |
69% |
NoneNone |
NoneNone |
View
|
| cholinergic receptor, muscarinic 4 |
HALOPROGIN |
Muscarinic M4 |
69% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2b |
DIPHENHYDRAMINE |
Adrenergic alpha2B |
69% |
NoneNone |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
DOXAZOSIN |
Adrenergic, Norepinephrine Transporter |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1, delta |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
AMOXAPINE |
Sodium Channel, Site 2 |
69% |
NoneNone |
NoneNone |
View
|
| amiloride-sensitive cation channel 5, intestinal |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type III, beta |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type VIII, alpha polypeptide |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type XI, alpha |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type I, beta |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type 10, alpha polypeptide |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IV, alpha polypeptide |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type V, alpha polypeptide |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type II, beta |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 gamma |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 beta |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type XI, alpha |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1, gamma |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1, delta |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type X, alpha |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IX, alpha |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage gated, type VIII, alpha |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type VII, alpha |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IV, beta |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IV, alpha |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type III, alpha |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type II, beta |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type II, alpha 2 |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type I, beta |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type I, alpha |
DESLORATADINE |
Sodium Channel, Site 2 |
67% |
NoneNone |
NoneNone |
View
|
| 3-hydroxy-3-methylglutaryl-Coenzyme A reductase |
ZAFIRLUKAST |
HMG-CoA Reductase |
67% |
NoneNone |
NoneNone |
View
|
| 3-hydroxy-3-methylglutaryl-Coenzyme A reductase |
ZAFIRLUKAST |
HMG-CoA Reductase |
67% |
NoneNone |
NoneNone |
View
|
| Cytochrom P450-2D6 monooxygenase |
KETOTIFEN |
CYP450-2D6 Inhibition |
67% |
NoneNone |
NoneNone |
View
|
| Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) |
ALOSETRON |
CYP450-2C9 Inhibition |
67% |
NoneNone |
NoneNone |
View
|
| cytochrome P450, family 2, subfamily C, polypeptide 9 |
ALOSETRON |
CYP450-2C9 Inhibition |
67% |
NoneNone |
NoneNone |
View
|
| Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) |
CHLORMADINONE ACETATE |
CYP450-2C9 Inhibition |
67% |
NoneNone |
NoneNone |
View
|
| cytochrome P450, family 2, subfamily C, polypeptide 9 |
CHLORMADINONE ACETATE |
CYP450-2C9 Inhibition |
67% |
NoneNone |
NoneNone |
View
|
| acetylcholinesterase (YT blood group) |
4-NONYLPHENOL |
Acetylcholinesterase |
67% |
NoneNone |
NoneNone |
View
|
| collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase |
4-NONYLPHENOL |
Acetylcholinesterase |
67% |
NoneNone |
NoneNone |
View
|
| acetylcholinesterase |
4-NONYLPHENOL |
Acetylcholinesterase |
67% |
NoneNone |
NoneNone |
View
|
| adenosine A2a receptor |
AMINOPHYLLINE |
Adenosine A2A |
67% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 1d (Non-specific probe) |
METHYLERGONOVINE |
Adrenergic alpha1D |
67% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2b |
AMITRAZ |
Adrenergic alpha2B |
67% |
NoneNone |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
GRAMICIDIN |
Adrenergic, Norepinephrine Transporter |
67% |
NoneNone |
NoneNone |
View
|
| bradykinin receptor, beta 2 |
GRAMICIDIN |
Bradykinin B2 |
67% |
NoneNone |
NoneNone |
View
|
| bradykinin receptor B2 |
GRAMICIDIN |
Bradykinin B2 |
67% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2a |
MOXONIDINE |
Adrenergic alpha2A |
67% |
NoneNone |
NoneNone |
View
|
| A3 adenosine receptor |
DIGITONIN |
Adenosine A3 |
67% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2b |
O-ANISIDINE |
Adrenergic alpha2B |
67% |
2.508uM |
1.145uM |
View
|
| neuropeptide Y receptor Y2 |
DIHYDROERGOCRISTINE MESYLATE |
Neuropeptide Y2 |
67% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
DEXTROMETHORPHAN |
Calcium Channel Type L, Benzothiazepine |
66% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
DEXTROMETHORPHAN |
Calcium Channel Type L, Benzothiazepine |
66% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
DEXTROMETHORPHAN |
Calcium Channel Type L, Benzothiazepine |
66% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
DEXTROMETHORPHAN |
Calcium Channel Type L, Benzothiazepine |
66% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
DEXTROMETHORPHAN |
Calcium Channel Type L, Benzothiazepine |
66% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
DEXTROMETHORPHAN |
Calcium Channel Type L, Benzothiazepine |
66% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2b |
EPERISONE |
Adrenergic alpha2B |
71% |
3.034uM |
1.385uM |
View
|
| adrenergic receptor, beta 1 |
BROMOCRIPTINE |
Adrenergic beta1 |
71% |
2.4uM |
1.386uM |
View
|
| adrenergic, beta-1-, receptor |
BROMOCRIPTINE |
Adrenergic beta1 |
71% |
2.4uM |
1.386uM |
View
|
| histamine receptor H 1 |
CITALOPRAM |
Histamine H1, Central |
71% |
3.194uM |
.371uM |
View
|
| adrenergic receptor, alpha 2a |
VERAPAMIL |
Imidazoline I2, Central |
71% |
5.524uM |
3.683uM |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
VERAPAMIL |
Imidazoline I2, Central |
71% |
5.524uM |
3.683uM |
View
|